Seattle-based biotech Good Therapeutics is being acquired by Roche, a Swiss pharmaceutical giant.
According to a release, Roche is paying $250 million in cash upfront for the purchase, which was announced Wednesday, and Roche will make additional payments for hitting certain milestones. The companies expect the deal to close in the third quarter.
